Optimal use of phosphate binders in chronic kidney disease

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 18, 2013, Pages 2521-2532

  Sonikian, Makrouhi ^a   Papachristou, Evangelos ^b   Goumenos, Dimitrios S ^b  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Aluminium; Calcium based phosphate binders; Chronic kidney disease; Hyperphosphatemia; Lanthanum; Sevelamer

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SALT; COLESTILAN; FERRIC HYDROXIDE; FIBROBLAST GROWTH FACTOR 23; IRON; IRON DEXTRAN; IRON OXYHYDROXIDE PHOSPHATE; KLOTHO PROTEIN; LANTHANUM; LANTHANUM CARBONATE; MAGNESIUM; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; MAGNESIUM SALT; NICOTINIC ACID; PA 21; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG;

ADD ON THERAPY; BLOOD VESSEL CALCIFICATION; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIUM SCORE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); METABOLIC ACIDOSIS; MORBIDITY; NONHUMAN; PATIENT COMPLIANCE; PHOSPHATE BALANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HYPERPARATHYROIDISM;

ALUMINUM HYDROXIDE; CALCIUM COMPOUNDS; CHELATING AGENTS; HUMANS; HYPERPHOSPHATEMIA; LANTHANUM; MAGNESIUM; PATIENT COMPLIANCE; PHOSPHATES; POLYAMINES; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84887925558     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.852183     Document Type: Review

References (94)

1. Liamis G, Milionis HJ, Elisaf M. Medication-induced hypophosphatemia: A review. Q J Med 2010;103:449-59
2. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8
3. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-8
4. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78:975-80
5. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF-23 in rats. J Clin Invest 2007;117:4003-8
6. Fukagawa M, Kazama JJ. With or without the kidney: The role of FGF23 in CKD. Nephrol Dial Transplant 2005;20:1295-8
7. Gutiérrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-15
8. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-92
9. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444:770-4
10. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011;22:124-36
11. Sliem H, Tawfik G, Moustafa F, Zaki H. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: A case-control study. Indian J Endocrinol Metab 2011;15:105-9
12. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998;31:607-17
13. Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96
14. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-42
15. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-Artery calcification in young adults with end stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
16. Kendrick J, Chonchol M. The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 2011;58:826-34
17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:1-201
18. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:1-130
19. Slatopolsky E, Caglar S, Pennell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971;50:492-9
20. Daugirdas JT, Chertow GM, Larive B, et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 2012;23:727-38
21. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008;9:2
22. Ahlenstiel T, Pape L, Ehrich JH, Kuhlmann MK. Self-Adjustment of phosphate binder to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephol Dial Transplant 2010;25:3241-9
23. Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012;60:90-101
24. Cannata-Andía JB, Ferńandez-Martín JL, Locatelli F, et al. Use of phosphatebinding agents is associated with a lower risk of mortality. Kidney Int 2013;Epub ahead of print
25. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010;56:842-51
26. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-96
27. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15
28. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-Analysis. Lancet 2013; Epub ahead of print
29. Plagemann T, Prenzler A, Mittendorf T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphatemia. Health Econ Rev 2011;1:1-9
30. Lafage MH, Combe C, Fournier A, Aparicio M. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992;42:1217-25
31. Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989;320:1110-13
32. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-61
33. Mai ML, Emmett M, Sheikh MS, et al. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989;36:690-5
34. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low-And high-calcium diets. Kidney Int 2012;81:1116-22
35. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013;83:959-66
36. Morinière P, Vinatier I, Westeel PF, et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988;3:651-6
37. Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 1996;49:163-7
38. Tzanakis I, Pras A, Kounali D, et al. Mitral annular calcifications in haemodialysis patients: A possible protective role of magnesium. Nephrol Dial Transplant 1997;12:2036-7
39. Spiegel DM, Farmer B. Long-Term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: A pilot study. Hemodial Int 2009;13:453-9
40. Turgut F, Kanbay M, Metin MR, et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008;40:1075-82
41. Ishimura E, Okuno S, Yamakawa T, et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007;20:237-44
42. de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/ magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: A controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-17
43. Emmett is A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int Suppl 2004(90):S25-32
44. Balasa RW, Murray RL, Kondelis NP, Bischel MD. Phosphate-binding properties and electrolyte content of aluminum hydroxide antacids. Nephron 1987;45:16-21
45. Sheikh MS, Maguire JA, Emmett M, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 1989;83:66-73
46. Drüeke TB. Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant 2002;17(Suppl 2):13-16
47. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-51
48. Mudge DW, Johnson DW, Hawley CM, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 2011;12:20-7
49. Hutchison AJ, Barnett ME, Krause R, et al. Long-Term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment. Nephron Clin Pract 2008;110:15-23
50. Pennick M, Poole L, Dennis K, Smyth M. Lanthanum carbonate reduces urine phosphorus excretion: Evidence of high-capacity phosphate binding. Ren Fail 2012;34:263-0
51. Hutchison AJ. Improving phosphatebinder therapy as a way forward. Nephrol Dial Transplant 2004;19(Suppl 1):19-24
52. Finn WF; SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006;65:191-202
53. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003(85):73-8
54. Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial 2011;15:176-84
55. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006;21:2217-24
56. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) 2011;16:290-8
57. Wilson R, Zhang P, Smyth M, Pratt R. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009;25:3021-8
58. Gonzalez-Parra E, Gonzalez-Casaus ML, Gaĺan A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011;26:2567-71
59. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71
60. Sonikian MA, Pani IT, Iliopoulos AN, et al. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7
61. De Santo NG, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006;19(Suppl 9):S108-14
62. Oka Y, Miyazaki M, Takatsu S, et al. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007;11:107-13
63. Sonikian M, Metaxaki P, Iliopoulos A, et al. Long-Term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. Ren Fail 2006;28:411-18
64. Pai AB, Shepler BM. Comparison of sevelamer hydrochloride and sevelamer carbonate: Risk of metabolic acidosis and clinical implications. Pharmacotherapy 2009;29:554-61
65. Delmez J, Block G, Robertson J, et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91
66. Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999;51:18-26
67. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3:1125-30
68. Daugirdas JT, Finn WF, Emmett M, Chertow GM; Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose. Semin Dial 2011;24:41-9
69. Chue CD, Townend JN, Moody et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013;24:842-52
70. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004;65:1914-26
71. Sprague SM, Ross EA, Nath SD, et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study. Clin Nephrol 2009;72:252-8
72. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96:2818-27
73. Salusky IB, Goodman WG, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005;16:2501-8
74. Ferreira A, Frazão JM, Monier-Faugere MC, et al. Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19:405-12
75. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003;64:441-50
76. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653-61
77. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
78. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61
79. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
80. Qunibi W, Moustafa M, Muenz LR, et al. CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
81. Barreto DV, Barreto Fde C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008;110:273-83
82. Raggi P, Vukicevic S, Moysés RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 2010;5(Suppl 1):31-40
83. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41
84. Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: A meta-Analysis. Nephrol Dial Transplant 2009;24:3168-74
85. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005;8:549-61
86. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-Term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14
87. Ferramosca E, Burke S, Chasan-Taber S, et al. Potential antiatherogenic and antiinflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149:820-5
88. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-Term experimental uremia. Kidney Int 2003;64:1653-61
89. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. Arthritis Rheum 2005;52:290-5
90. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5:286-91
91. Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8:280-9
92. McIntyre CW, Pai P, Warwick G, et al. Iron magnesium hydroxycarbonate (fermagate): A novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009;4:401-9
93. Chenq SC, Young DO, Huanq Y, et al. A randomized, double-blind, placebocontrolled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
94. Locatelli F, Dimkovic N, Spasovski G. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: A randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant 2013;28:1874-88.